Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

An alternative therapy against brucellosis

18.01.2006


Concepción Lecároz, a researcher from the University of Navarra, has developed a new therapy against brucellosis. This zoonosis —a disease or infection of animals which can be transmitted to humans under natural conditions— annually affects 500,000 people worldwide. This research project forms part of her doctoral thesis, defended at the University’s School of Pharmacy.



This study has permitted the development of a new treatment which significantly reduces infections in mice, as opposed to the traditional treatment with “free” (unencapsulated) antibiotics with short treatment times. Despite the fact that brucellosis is highly susceptible to the majority of antibiotics, the indices of relapse in humans ranges from 5 to 15% depending on the antibiotic regimen; in any case, standard treatment requires combined therapy during long periods of time.

The alternative treatment developed by Ms. Lecároz involves the transportation of the antibiotic gentamicina to infected cells by means of biodegradable particles, which can produce a much higher concentration of antibiotic precisely in the organs which are infected. These biodegradable systems are designed in such a way that they release the antibiotic in a controlled manner, which allows therapeutic levels of antibiotics after a reduced number of dosages.


The next step: human trials

In this research project, Concepción Lecároz has achieved a significant reduction of spleen pathogens in mice, which has led to the possibility of achieving similar results in humans.

In Spain, along with tuberculosis and meningococcal meningitis, brucellosis is one of the most frequent endemic bacterial pathologies. The characteristic symptoms of the disease are fever, chills, weakness, muscular pain, sweating and headaches. If the bacteria invades the bloodstream, it can infect numerous tissues and organs, such as the liver, the spleen, the bones, the genitourinary system, the lungs, the central nervous system, and the heart, to the point of even endangering the life of the patient.

Irati Kortabitarte | alfa
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&Berri_Kod=858&hizk=I

More articles from Life Sciences:

nachricht High-Speed Locomotion Neurons Found in the Brainstem
24.10.2017 | Universität Basel

nachricht Antibiotic resistance: a strain of multidrug-resistant Escherichia coli is on the rise
24.10.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Single nanoparticle mapping paves the way for better nanotechnology

24.10.2017 | Physics and Astronomy

A quantum spin liquid

24.10.2017 | Physics and Astronomy

Antibiotic resistance: a strain of multidrug-resistant Escherichia coli is on the rise

24.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>